Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px
Document › Details

Inivata Ltd.. (3/28/19). "Press Release: Inivata Completes $52.6m (£39.8m) Series B Funding Round". Research Triangle Park, NC & Cambridge.

Organisations Organisation Inivata Ltd.
  Organisation 2 RT Ventures (RT Capital)
Products Product InVisionFirst™-Lung liquid biopsy test
  Product 2 venture capital
Index term Index term Inivata–SEVERAL: investment, 201808–201903 financing round Series B £39.8m incl new investor RT Ventures + existing investors
Persons Person Morris, Clive (Inivata 201807– CEO joinde 201605 before AstraZeneca)
  Person 2 Gardner, Chris (Consilium 201507– Partner before since 2003 at Citigate Dewe Rogerson London)
     


Funds will accelerate commercialization of InVisionFirst-Lung Liquid Biopsy test and the development of the InVision® liquid biopsy platform into new indications


Inivata, a leader in liquid biopsy, today announces the completion of a Series B fundraising of $52.6m (£39.8 million).

Existing investors Woodford Patient Capital Trust, IP Group, Cambridge Innovation Capital and Johnson & Johnson Innovation – JJDC all participated in the round alongside new investor RT Ventures. The first close of the financing occurred in August 2018, with the final tranche of the over-subscribed round being received in March 2019, based on strong delivery against corporate milestones.

The funds will be used to advance the US commercial roll-out of the Company’s InVisionFirst™-Lung liquid biopsy test, which recently received coverage determination for US Medicare patients with advanced non-small cell lung cancer (NSCLC), paving the way for the test to be used in routine clinical care. This liquid biopsy test uses a simple blood draw to detect clinically relevant cancer mutations to provide molecular insights relevant to that patient. InVisionFirst-Lung is commercially available in the US.

The Series B financing will also enable the Company to accelerate the development of the InVision® liquid biopsy platform into new indications to drive the future growth of the Company.

Clive Morris, Chief Executive Officer at Inivata, said: “This Series B financing allows us to commercialize our lead product in patients with advanced lung cancer, following our positive reimbursement decision. We also have an exciting portfolio of future products that will be advanced in parallel to maximize the benefits of our industry-leading InVision Liquid Biopsy platform to patients. We are grateful to our existing investors for their continued support and are delighted to welcome RT Ventures to our already strong investor base. With these funds in place, we look forward to continuing our mission to transform the lives of cancer patients through the power of liquid biopsy.”


About Inivata

Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood test to transform the care of cancer patients. The Company’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge and reinforced by multiple high calibre publications. Its lead product, InVisionFirst™-Lung, is commercially available and provides molecular insights that enable clinicians to make more informed treatment decisions for NSCLC patients. Inivata is partnering with pharmaceutical and biotechnology companies on InVisionFirst™-Lung and its wider platform, which is applicable to a range of cancer types. The Company has a CLIA laboratory in Research Triangle Park, NC and laboratories in Cambridge, UK. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata.


Media Contacts:

Consilium Strategic Communications
Chris Gardner/Angela Gray/Sarah Wilson
inivata@consilium-comms.com
+44 (0)20 3709 5700

Karen Chandler-Smith
karen.chandler-smith@inivata.com
+44 (0)7900 430235

Investor Contact:

LifeSci Advisors
Bob Yedid
bob@lifesciadvisors.com
+1 646-597-6989

   
Record changed: 2019-04-03

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Inivata Ltd.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group BioPharm America 2019 Boston September 650x65px




» top